DRUG
Vasopressin (USP) Injectable Solution [Vasostrict]
Nasal Spray
Status
Completed
Phase
Phase 2 / Phase 3
Enrollment
157
Locations
1
Results
Posted
Publications
0
Study summary
The purpose of this clinical trial is to investigate the effectiveness of vasopressin nasal spray for treating symptoms associated with autism. Vasopressin is a hormone that is produced naturally within the body and has been implicated in regulating social behaviors. It has been proposed that administration of the hormone may also help improve social functioning in individuals with autism.
Interventions
DRUG
Nasal Spray
DRUG
Placebo Nasal Spray
Timeline
First posted
Jul 2, 2017
Study start
Feb 20, 2018
Primary completion
Mar 18, 2024
Study completion
Mar 18, 2024
Results posted
Sep 19, 2025
Registry updated
Jun 4, 2026
Outcomes
Change From Baseline in Parent Rated Social Responsiveness Scale, Second Edition (SRS-2) Total Scores During Treatment.
Time frame · baseline, 4-week, 8-week
Social Responsiveness Scale, 2nd Edition (SRS) scores measure social abilities with lower scores meaning better social abilities. The SRS-2 is reported as a total score (T-Score Range: 37 to above 90), and the Diagnostic and Statistical Manual of Mental Disorders (DSM)-5-compatible Social Communication and Interaction (SCI) score (T-Score Range: 36 to above 90) and Restricted Interests and Repetitive Behavior (RRB) score (T-Score range: 41 to above 90). A T-score of 50 indicates the population mean with a standard deviation of 10. Higher scores correspond to greater symptom levels (≤ 59: within normal limits; 60-65: mild range; 66-75: moderate range; ≥ 76: severe range). Change is reported as 4-week minus the baseline score, and 8-week minus the 4-week score. For this outcome, the baseline score is the average of the screening visit and baseline visit (average approximately 2 to 3 weeks after the screening visit).
Change From Baseline in Clinical Global Impression (CGI) Scores During Treatment.
Time frame · baseline; 4-week; 8-week
Clinician assessment of CGI severity (CGI-S) and CGI improvement (CGI-I) scores. * Higher scores on the CGI-S mean greater social and communication deficits (range: 1 to 7). * Lower scores on the CGI-I correspond to greater improvement in the areas assessed in the CGI-S, and higher scores correspond to worsening (range: 1 to 7). There is no baseline score for the CGI-I, it represents the clinician's subjective assessment of change.
Change From Baseline on Reading the Mind in the Eyes Test (RMET) During Treatment.
Time frame · baseline; 4-week; 8-week
Score range: 0 to 28; higher scores mean better ability to read emotions and lower scores mean worse ability to read emotions.
Change From Baseline on the Facial Emotion Recognition Test During Treatment.
Time frame · baseline; 4-week; 8-week
Score range: 0 to 42; higher scores mean better facial emotion recognition abilities. Lower scores mean worse facial emotion recognition abilities.
Change From Baseline in Parent Rated Repetitive Behavior Scale Revised (RBS-R) Scores During Treatment.
Time frame · baseline; 4-week; 8-week
Score range: 0 to 129; higher scores on the RBS-R mean higher levels of repetitive and restricted behaviors.
Change From Baseline in Parent Rated Spence Children's Anxiety Scale (SCAS) During Treatment.
Time frame · baseline; 4-week; 8-week
Scale measuring severity of anxiety symptoms. Score range: 0 to 114; higher scores mean higher levels of anxiety, lower scores mean lower levels of anxiety.
Change From Baseline on Electrocardiogram (EKG) P Duration During Treatment.
Time frame · baseline to 4-week, 8-week, and 12-week
Change From Baseline on Electrocardiogram (EKG) PR Interval During Treatment.
Time frame · baseline to 4-week, 8-week, and 12-week
Change From Baseline on Electrocardiogram (EKG) QRS Interval During Treatment.
Time frame · baseline to 4-week, 8-week, and 12-week
Change From Baseline on Electrocardiogram (EKG) QT Interval During Treatment.
Time frame · baseline to 4-week, 8-week, and 12-week
Change From Baseline on Blood Clinical Labs (Sodium) During Treatment.
Time frame · baseline to 4-week, 8-week, and 12-week
Eligibility
Inclusion Criteria: * Medically healthy outpatients between 6 and 17 years of age; * Diagnostic and Statistical Manual 5th edition (DSM-5) criteria for Autism Spectrum Disorder (ASD) on the basis of clinical evaluation, confirmed with the Autism Diagnostic Interview Revised (ADI-R) and Autism Diagnostic Observation Schedule, Second Edition (ADOS-2) or Childhood Autism Rating Scale, Second Edition (CARS-2); * males and females; * intelligence quotient (IQ) of 40 and above; * rating of 4 or higher on the Social Communication domain of the Clinical Global Impressions Severity (CGI-S); * Social Responsiveness Scale-2 Total Score of 70 and above; * care provider who can reliably bring participant to clinic visits, provide trustworthy ratings, and interacts with participant on a regular basis; * stable concomitant psychotropic medications or medications potentially affecting vasopressin for at least 4 weeks (with the exception of fluoxetine, 6 weeks); * no planned changes in psychosocial and biomedical interventions during the trial; * willingness to provide blood samples and ability to participate in key study procedures (i.e., diagnostic assessments and laboratory safety measurements). Exclusion Criteria: * DSM-5 diagnosis of schizophrenia, schizoaffective disorder, or psychotic disorder; * regular nasal obstruction or nosebleeds; * unstable medical conditions such as migraine, asthma attacks, or seizures, and significant physical illness (e.g. serious liver disease, renal dysfunction, or cardiac pathology); * clinically significant abnormal electrocardiogram reading; * history of hypersensitivity to vasopressin, its analogs, or compounding preservatives (e.g., chlorobutanol); * evidence of a genetic mutation known to cause ASD or intellectual disability (e.g., Fragile X Syndrome); or metabolic, or infectious etiology for ASD on the basis of medical history, neurologic history, and available tests for inborn errors of metabolism and chromosomal analysis; * significant hearing or vision impairments; * habitually drinks large volumes of water; * pregnant or sexually active females not using a reliable method of contraception; * current use of any medications known to interact with vasopressin including: 1) carbamazepine (i.e., Tegretol); chlorpropamide; clofibrate; urea; fludrocortisone; tricyclic antidepressants (all of which may potentiate the antidiuretic effect of vasopressin when used concurrently); 2) demeclocycline; norepinephrine; lithium; heparin; alcohol (all of which may decrease the antidiuretic effect of vasopressin when used concurrently); 3) ganglionic blocking agents including benzohexonium, chlorisondamine, pentamine (all of which may produce a marked increase in sensitivity to the pressor effects of vasopressin); * previous participation in a vasopressin clinical trial or current use of vasopressin; * current use of desmopressin (DDAVP) or oxytocin.
Study locations
United States. Showing up to 24 locations stored in the fast local snapshot.
Stanford University
Stanford, California, United States
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
First Affiliated Hospital, Sun Yat-Sen University · Liver Neoplasms · Postoperative Complications
Not applicable
Completed
161
2026-07
Montefiore Medical Center · Cervical Preparation
Phase 1
Recruiting
94
2026-07
Elizabeth Austen Lawson · Vasopressin Deficiency
Phase 1
Recruiting
40
2026-07
Massachusetts General Hospital · Arginine Vasopressin Deficiency · Oxytocin Deficiency
Early Phase 1
Recruiting
20
2026-07
Zhaoyun Zhang · Craniopharyngiomas · Pituitary Macroadenoma
Phase 4
Enrolling by invitation
152
2026-07
Otsuka Pharmaceutical Development & Commercialization, Inc. · Hyponatremias · Water Intoxication
Phase 3
Completed
205
2026-07
Otsuka Pharmaceutical Development & Commercialization, Inc. · Hyponatremia
Phase 3
Completed
243
2026-07
Beijing Friendship Hospital · Kidney Transplant · Delayed Graft Function
Not applicable
Active, not recruiting
150
2026-07
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.